BNT162b2_vaccine_efficacy_data.png
Size of this preview:
781 × 600 pixels
.
Other resolutions:
313 × 240 pixels
|
625 × 480 pixels
|
1,000 × 768 pixels
|
1,120 × 860 pixels
.
Summary
| Description |
English:
Cumulative incidence curves for the first COVID-19 occurrence after first dose of Tozinameran (BNT162b2) or placebo (all-available efficacy population) in double-blind clinical trial submitted to the U.S. FDA for EUA by Pfizer-BioNTech. (red: placebo; blue: BNT162b2)
|
| Date | |
| Source | https://www.fda.gov/media/144245/download (p30) |
| Author | U.S Food and Drug Administration and Pfizer Inc. |
Licensing
|
This chart is
ineligible for
copyright
and therefore in the
public domain
, because it consists entirely of information that is common property and contains no original authorship. For more information, see
Commons:Threshold of originality § Charts
|